Summary Thirty-one patients with stage ilA (N2) non-small-cell lung cancer were randomized to receive radiotherapy alone or chemotherapy with cisplatin and vinblastine followed by surgery. Response rates to induction chemotherapy and radiotherapy were 50% and 53.3% respectively. Complete surgical resection was possible for 62.5% of patients. Median survival times were 16.2 and 18.7 months for radiotherapy alone and chemotherapy-surgery respectively (P= Ns), with no long-term improvement in survival seen with combined-modality treatment.
Until recently. standard treatment for patients with stage III nonsmall-cell lung cancer (NSCLC) has been thoracic irradiation alone. The addition of systemic chemotherapy to radiotherapy results in a modest improvement in median survival. but 5-year survival remains less than 15% (Stewart. 1995) . The combination of induction chemotherapy and surgery for stage III NSCLC has been assessed in several phase H studies. all of which have confirmed the safety and feasibility of this approach (Shepherd. 1993 : Albain. 1993 ). Most investigators report 5-year survival rates of approximately 25%.
To determine whether this apparent improvement in survival truly was due to combined-modality treatment with surgery rather than to patient selection bias. the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) initiated a randomized trial of thoracic irradiation alone vs induction chemotherapy and surgery for patients with stage hIA NSCLC. The trial closed prematurely when the Radiation Therapy Oncology Group study 88-08 showed a 31% 2-year survival rate for chemo-radiotherapy compared with 20% for radiation alone (Sause et al. 1995) . It was felt by Canadian investigators that a radiation-alone control arm was no longer appropriate. However. important observations have arisen from the study that have relevance to ongoing trials of combined-modality therapy in the UK and North America. Toxicity Grade 3 and 4 haematological toxicity and nausea and vomiting were confined to the patients who had chemotherapy. The median nadir granulocyte and platelet counts were 0.2 x 109 1-1 (0.01-2.3 x 109 1-') and 166 x 109 1-1 (85-269 x 109 1-' respectively. Three patients had febrile neutropenia. but no patient suffered a toxic death as a result of chemotherapy. One patient had grade 3 radiation pneumonitis. but none had grade 3 or 4 oesophagitis. Post-operative complications included arrythmia (three patients), prolonged ventilation (two patients), and prolonged air leak. infection and atelectasis (one patient each).
PATIENTS AND METHODS

Relapse and survival
There have been eight local and one systemic relapses in the chemotherapy and surgery arm, and six local and four systemic relapses in the radiation arm. Median survival for patients treated with radiation was 16.2 months . compared with 18.7 months (CI 12.8-32 months) for those on combinedmodality therapy (Figure 1 ).
DISCUSSION
In both Europe and North America. induction chemotherapy followed by surgery has gained widespread acceptance as a treatment for stage L1A NSCLC despite an absence of clinical trial data that document its superiority over thoracic irradiation, either alone or combined with chemotherapy. There have been three randomized trials of induction chemotherapy and surgery published to date, but all three had surgery in both arms (Pass et al. 1992 : Roth et al. 1994 Rosell et al, 1994) . The lack of a nonsurgical control arm is a major weakness of these studies as most patients with stage [HA NSCLC are not considered to have tumours that are resectable for cure. even though they may be technically resectable.
In one trial (Roth et al. 1994) . surgery alone was compared with induction chemotherapy followed by surgery. In the other two British Journal of Cancer (1998) 78(5) trials. surgery with post-operative radiation was compared with induction chemotherapy followed by surgery (Pass et al. 1992) or induction chemotherapy. surgery and post-operative radiotherapy (Rosell et al. 1994) . Despite variability in the choice of induction chemotherapy and administration of thoracic irradiation. they all had similar results. Both median and 3-year survival rates were superior in the treatment arms that included chemotherapy. and the differences were statistically significant in two trials (Rosell et al. 1994 : Roth et al. 1994 superior to thoracic irradiation alone. We felt that the lack of longterm benefit in most of the randomized trials of radiation with or without chemotherapy was adequate justification for the radiation-alone control arm. We also felt that prolongation of only short-term or median survival should not be the goal of combined-modality surgical treatment. and so our study was designed initially to detect a doubling of 3-year survival from 12.5%7 to 25% and would have required 240 patients. Because of early closure. our results clearly are not definitive. but the lack of any trend towards improved survival with combined-modality therapy should lead investigators to question more strongly whether the survival advantage seen in the Roth and Rosell studies might have been due to imbalances in critical prognostic factors rather than to true superiority of chemotherapy and surgery. In support of this are the results of a 47-patient study from the Cancer and Acute Leukemia Group B (CALGB). in which surgery and radiation was compared with chemotherapy with etoposide and cisplatin followed by surgerv and radiation @ Cancer Research Campaign 1998 CT and surgery vs RT for stage IIIA NSCLC 685 (Elias et al. 1997) . The median survival of the patients in the chemotherapy arm was only 19 months compared with 23 months for the patients who did not receive chemotherapy (P = 0.64).
